Announcements

Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million (USD$4.9 million) in an oversubscribed Series A2 investment round. GPN Vaccines has created...

Adelaide, Australia, 25 May 2020 – GPN Vaccines is pleased to announce Dr Ismail Kola has joined the Company’s Board of Directors. Dr Kola is a Senior Partner at Forepont Capital, a New York-based venture capital firm investing in pharmaceutical and biotechnology companies that improve healthcare outcomes....

Adelaide, Australia, 7 April 2020 – GPN Vaccines is pleased to announce the appointment of Dr Paul Wabnitz as the Company's Medical Director and Mr Jim Ackland as Director, Regulatory & Quality. These two appointments will significantly strengthen the clinical development team in preparation for...

Adelaide, Australia, 18 November 2019 – GPN Vaccines is pleased to announce Dr Lauren Giorgio has been appointed as the Company’s Chief Operating Officer. Lauren brings valuable experience in intellectual property management, business development, stakeholder engagement, commercialisation and operations in the life sciences sector, encompassing the...

Protecting children and adults from the world’s foremost bacterial pathogen